Neurocrine Acquires Soleno for $2.9B
Analysis based on 8 articles · First reported Apr 06, 2026 · Last updated Apr 06, 2026
The acquisition of MiNK Therapeutics by Neurocrine Biosciences for $2.9 billion is expected to significantly boost Neurocrine Biosciences' revenue growth and diversify its portfolio with the addition of VYKAT XR. This deal provides a substantial premium for MiNK Therapeutics' shareholders and strengthens Neurocrine Biosciences' position in the endocrinology and rare disease markets.
Neurocrine Biosciences has entered into a definitive agreement to acquire MiNK Therapeutics for $2.9 billion, or $53.00 per share in cash. This acquisition will expand Neurocrine Biosciences' portfolio by adding VYKAT XR, a first-in-class FDA-approved treatment for hyperphagia in Prader-Willi syndrome. VYKAT XR has shown strong early commercial performance, generating $190 million in 2025 revenue. The transaction, approved by both boards, is expected to close within 90 days and will be funded by Neurocrine Biosciences with cash on hand and debt. This strategic move aims to accelerate Neurocrine Biosciences' revenue growth, diversify its product offerings, and strengthen its leadership in rare diseases, leveraging its existing commercial infrastructure to expand VYKAT XR's reach.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard